Interv Akut Kardiol. 2024;23(1):33-36 | DOI: 10.36290/kar.2024.001

Pharmacological stress test using regadenoson in conventional and dynamic cardiac SPECT

Milan Kamínek1, 2, Vladimír Kincl2, Martin Havel1, 3
1 Klinika nukleární medicíny, LF UP a Fakultní nemocnice Olomouc
2 Mezinárodní centrum klinického výzkumu, Fakultní nemocnice u sv. Anny, Masarykova univerzita, Lékařská fakulta, Brno
3 Klinika nukleární medicíny, LF Ostravské univerzity a Fakultní nemocnice Ostrava

Regadenoson as a selective A2A adenosine enables pharmacological stress when exercise stress techniques would be impossible or very difficult. We present two case reports demonstrating its advantages. In case 1, we initially attempted to induce stress using physical exercise in a 77-year-old male patient after coronary artery bypass graft. Due to inadequate heart rate increase, the stress was promptly converted to pharmacological stress using regadenoson in combination with a low level of exercise. Single-photon emission computed tomography (SPECT) showed extensive ischaemia of the lateral wall. Coronary angiography subsequently revealed vein graft occlusion at the left circumflex artery. Case 2 demonstrates recent advances in SPECT technology. Modern multidetector Cadmium Zinc Telluride (CZT) cameras enable dynamic acquisition and quantification of coronary flow reserve (CFR). It can be helpful in identifying multivessel disease or microvascular ischaemia. CFR is calculated as the ratio between myocardial blood flow during stress vasodilator hyperaemia and flow at rest. In a 50-year-old diabetic patient, a conventional cardiac SPECT showed normal post-stress left ventricular perfusion and function. Dynamic SPECT showed normal myocardial blood flow (MBF) and normal CFR ≥ 2. During 18 months of follow-up, no cardiac event was observed in this patient.

Keywords: regadenoson, cardiac SPECT, dynamic SPECT, MBF, CFR.

Received: October 13, 2023; Revised: February 9, 2024; Accepted: February 14, 2024; Published: April 29, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kamínek M, Kincl V, Havel M. Pharmacological stress test using regadenoson in conventional and dynamic cardiac SPECT. Interv Akut Kardiol. 2024;23(1):33-36. doi: 10.36290/kar.2024.001.
Download citation

References

  1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;14:407-477. Go to original source... Go to PubMed...
  2. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165. Go to original source... Go to PubMed...
  3. Verberne HJ, Acampa W, Anagnostopoulos3 C, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging. 2015;42:1929-1940. Go to original source... Go to PubMed...
  4. Havel M, Koranda P, Kincl V, et al. Additional Value of the Coronary Artery Calcium Score in Patients for whom Myocardial Perfusion Imaging is Challenging. Kardiol Pol. 2019;11;77:458-464. Go to original source... Go to PubMed...
  5. Lieu HD, Shryock JC, von Mering GO, et al. Rapiscan, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007;14:514-520. Go to original source... Go to PubMed...
  6. Mahmarian JJ, Cerqueira MD, Iskandrian AE, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging. 2009;2:959-68. Go to original source... Go to PubMed...
  7. Johnson NP, Gould KL, Di Carli MF, et al. Invasive FFR and Noninvasive CFR in the Evaluation of Ischemia: What Is the Future? J Am Coll Cardiol. 2016;67:2772-2788. Go to original source... Go to PubMed...
  8. Schindler TH, Schelbert HR, Quercioli A, et al. Cardiac PET paging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging. 2010;3:623-40. Go to original source... Go to PubMed...
  9. Kincl V, Kamínek M, Vašina J, et al. Feasibility of ultra low-dose thallium stress-redistribution protocol including prone imaging in obese patients using CZT camera. International Journal of Cardiovascular Imaging. 2016;32:1463-1469. Go to original source... Go to PubMed...
  10. Hyafil F, Gimelli A, Slart R, et al. EANM procedural guidelines for myocardial perfusion scintigraphy using cardiac-centered gamma cameras. Eur J Hybrid Imaging. 2019;3:11. Go to original source... Go to PubMed...
  11. Agostini D, Roule V, Nganoa C, et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging. 2018;45:1079-1090. Go to original source... Go to PubMed...
  12. Nkoulou R, Fuchs TA, Pazhenkottil AP, et al. Absolute Myocardial Blood Flow and Flow Reserve Assessed by Gated SPECT with Cadmium-Zinc-Telluride Detectors Using 99mTc-Tetrofosmin: Head-to-Head Comparison with 13N-Ammonia PET. J Nucl Med. 2016;57:1887-1892. Go to original source... Go to PubMed...
  13. Giubbini R, Bertoli M, Durmo R, et al. Comparison between N13NH3-PET and 99mTc-Tetrofosmin-CZT SPECT in the evaluation of absolute myocardial blood flow and flow reserve. J Nucl Cardiol. 2021;28:1906-1918. Go to original source... Go to PubMed...
  14. Havel M, Kaminek M, Klegova A, et al. Prognostic Value of Myocardial Blood Flow and Coronary Flow Reserve on Dynamic Myocardial SPECT. Eur J Nucl Med Mol Imaging .2023;50(Suppl 1):S605-S606.
  15. Giri S, Shaw LJ, Murthy DR, et al. Impact of Diabetes on the Risk Stratification Using Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging in Patients With Symptoms Suggestive of Coronary Artery Disease. Circulation. 2002;105:32-40. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.